Spravato® Therapy for Treatment-Resistant Depression
Fast-acting, FDA-approved relief when traditional antidepressants haven’t worked.
What is Spravato®?
Spravato® (esketamine) is the only FDA-approved nasal spray for adults with treatment-resistant depression (TRD) or major depressive disorder (MDD) with suicidal thoughts. Unlike standard antidepressants, it targets different brain pathways and can provide rapid relief—sometimes within hours.
What to Expect
Schedule an Initial Evaluation and sign the consent form (and any additional forms) prior to your first visit.
Step 1
A psychiatry provider will review your mental health conditions, medical history, and discuss the risks & benefits.
Step 2
If you have tried 2+ antidepressants with little to no improvement, we’ll apply for Spravato insurance coverage.
Step 3
Standard Treatment Protocol
Once you and your provider agree that Spravato® (esketamine) nasal spray is an appropriate option—and you’ve reviewed both the potential benefits and risks—you can begin planning your treatment journey.
Your provider will help determine whether treatment should be used in addition to a traditional oral antidepressant based on your individual needs and history.
Treatment typically begins with two sessions per week during the first month, followed by weekly sessions in the second month. After that, you and your provider can assess your progress and decide on the most appropriate treatment schedule moving forward.
In each session, you will administer the Spravato® nasal spray yourself, with two hours of monitoring for side effects by your provider. You will need a ride home afterwards, as driving after treatment is not allowed.